FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362522684> ?p ?o ?g. }

• W4362522684 abstract "Non-steroidal anti-inflammatory drugs (NSAIDs) and analgesics are used frequently by athletes either prophylactically for the prevention of pain, or to accelerate recovery following an injury. However, these types of pain management strategies have been shown to inhibit signalling pathways (e.g., cyclooxygenase-2) that may hinder muscular adaptations such as hypertrophy and strength. Nutraceuticals such as palmitoylethanolamide (PEA) have analgesic properties that act via different mechanisms to NSAIDS/analgesics. Furthermore, PEA has been shown to have a positive effect on sleep and may contribute positively to muscle hypertrophy via PKB activation. Although PEA has not been widely studied in the athletic or recreationally active population, it may provide an alternative solution for pain management if it is found not to interfere with, or enhance training adaptations. Therefore, the study aim is to investigate the effects of daily PEA supplementation (Levagen + ®) with resistance training on lean body mass, strength, power and physical performance and outcomes of recovery (e.g., sleep) compared to placebo.This double-blind, randomised controlled study will take place over an 11-week period (including 8-weeks of progressive resistance training). Participants for this study will be 18-35 years old, healthy active adults that are not resistance trained. Participants will attend a familiarisation (week 0), pre-testing (week 1) and final-testing (week 11). At the pre-testing and final-testing weeks, total lean body mass (dual-energy X-ray absorptiometry; DXA), total mid-thigh cross sectional area (pQCT), maximal muscular strength (1 repetition maximum bench press, isometric mid-thigh pull) and power (countermovement jump and bench throw) will be assessed. Additionally, circulating inflammatory cytokines and anabolic hormones, sleep quality and quantity (ActiGraph), pain and subjective wellbeing (questionnaires) will also be examined.This study is designed to investigate the effects that PEA may have on pre-to post intervention changes in total body and regional lean muscle mass, strength, power, sleep, subjective wellbeing, and pain associated with resistance training and menstruation compared with the placebo condition. Unlike other NSAIDs and analgesics, which may inhibit muscle protein synthesis and training adaptations, PEA which provides analgesia via alternative mechanisms may provide an alternative pain management solution. It is therefore important to determine if this analgesic compound interferes with or enhances training adaptations so that athletes and active individuals can make an informed decision on their pain management strategies.Australian New Zealand Clinical Trials Registry (ANZCTR: ACTRN12621001726842p)." @default.
• W4362522684 created "2023-04-06" @default.
• W4362522684 creator A5008623539 @default.
• W4362522684 creator A5014868735 @default.
• W4362522684 creator A5025871708 @default.
• W4362522684 creator A5027885533 @default.
• W4362522684 creator A5030001403 @default.
• W4362522684 creator A5030050502 @default.
• W4362522684 creator A5031255469 @default.
• W4362522684 creator A5035036839 @default.
• W4362522684 creator A5035102680 @default.
• W4362522684 creator A5044238636 @default.
• W4362522684 creator A5044782077 @default.
• W4362522684 creator A5045075638 @default.
• W4362522684 creator A5046655415 @default.
• W4362522684 creator A5083248827 @default.
• W4362522684 creator A5084706531 @default.
• W4362522684 creator A5088651820 @default.
• W4362522684 date "2023-03-31" @default.
• W4362522684 modified "2023-10-01" @default.
• W4362522684 title "A randomised controlled trial assessing the potential of palmitoylethanolamide (PEA) to act as an adjuvant to resistance training in healthy adults: a study protocol" @default.
• W4362522684 cites W120103911 @default.
• W4362522684 cites W1433747404 @default.
• W4362522684 cites W1820279957 @default.
• W4362522684 cites W1960751147 @default.
• W4362522684 cites W1977095014 @default.
• W4362522684 cites W1977380331 @default.
• W4362522684 cites W2011076485 @default.
• W4362522684 cites W2040603894 @default.
• W4362522684 cites W2052875910 @default.
• W4362522684 cites W2066914724 @default.
• W4362522684 cites W2068924751 @default.
• W4362522684 cites W2086859574 @default.
• W4362522684 cites W2096213349 @default.
• W4362522684 cites W2126651813 @default.
• W4362522684 cites W2130247249 @default.
• W4362522684 cites W2137981670 @default.
• W4362522684 cites W2146630750 @default.
• W4362522684 cites W2151487996 @default.
• W4362522684 cites W2152587910 @default.
• W4362522684 cites W2162983253 @default.
• W4362522684 cites W2166023752 @default.
• W4362522684 cites W2168107233 @default.
• W4362522684 cites W2351799718 @default.
• W4362522684 cites W2405713730 @default.
• W4362522684 cites W2413311099 @default.
• W4362522684 cites W2514974009 @default.
• W4362522684 cites W2583161188 @default.
• W4362522684 cites W2742520441 @default.
• W4362522684 cites W2746772208 @default.
• W4362522684 cites W2746946619 @default.
• W4362522684 cites W2805195050 @default.
• W4362522684 cites W2809906247 @default.
• W4362522684 cites W2936341633 @default.
• W4362522684 cites W3007350124 @default.
• W4362522684 cites W3022089061 @default.
• W4362522684 cites W3128571604 @default.
• W4362522684 cites W3138589817 @default.
• W4362522684 cites W3155978397 @default.
• W4362522684 cites W3162987602 @default.
• W4362522684 cites W3199517147 @default.
• W4362522684 doi "https://doi.org/10.1186/s13063-023-07199-y" @default.
• W4362522684 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37004121" @default.
• W4362522684 hasPublicationYear "2023" @default.
• W4362522684 type Work @default.
• W4362522684 citedByCount "0" @default.
• W4362522684 crossrefType "journal-article" @default.
• W4362522684 hasAuthorship W4362522684A5008623539 @default.
• W4362522684 hasAuthorship W4362522684A5014868735 @default.
• W4362522684 hasAuthorship W4362522684A5025871708 @default.
• W4362522684 hasAuthorship W4362522684A5027885533 @default.
• W4362522684 hasAuthorship W4362522684A5030001403 @default.
• W4362522684 hasAuthorship W4362522684A5030050502 @default.
• W4362522684 hasAuthorship W4362522684A5031255469 @default.
• W4362522684 hasAuthorship W4362522684A5035036839 @default.
• W4362522684 hasAuthorship W4362522684A5035102680 @default.
• W4362522684 hasAuthorship W4362522684A5044238636 @default.
• W4362522684 hasAuthorship W4362522684A5044782077 @default.
• W4362522684 hasAuthorship W4362522684A5045075638 @default.
• W4362522684 hasAuthorship W4362522684A5046655415 @default.
• W4362522684 hasAuthorship W4362522684A5083248827 @default.
• W4362522684 hasAuthorship W4362522684A5084706531 @default.
• W4362522684 hasAuthorship W4362522684A5088651820 @default.
• W4362522684 hasBestOaLocation W43625226841 @default.
• W4362522684 hasConcept C120863210 @default.
• W4362522684 hasConcept C126322002 @default.
• W4362522684 hasConcept C142724271 @default.
• W4362522684 hasConcept C147583825 @default.
• W4362522684 hasConcept C148001335 @default.
• W4362522684 hasConcept C170493617 @default.
• W4362522684 hasConcept C1862650 @default.
• W4362522684 hasConcept C202061045 @default.
• W4362522684 hasConcept C204787440 @default.
• W4362522684 hasConcept C27081682 @default.
• W4362522684 hasConcept C2777767828 @default.
• W4362522684 hasConcept C2778938600 @default.
• W4362522684 hasConcept C2908647359 @default.
• W4362522684 hasConcept C2991744798 @default.
• W4362522684 hasConcept C71924100 @default.
• W4362522684 hasConcept C99454951 @default.

• next